News

Pharmetheus at QSPC in Leiden, 2022

Pharmetheus will be at QSPC2022 – Quantitative Systems Pharmacology Conference in Leiden in April 20-22! We love to chat about MIDD vision and advancements, PBPK-QSP applications and software, career opportunities and support for

Read More »

Welcome Efosa Alohan!

We are glad to welcome Efosa Alohan, Analyst System Developer, to Pharmetheus. Efosa will be based in Uppsala. His experience includes system- and web development, and tech team leading in e-commerce and

Read More »

Pharmetheus at WCoP in Cape Town, 2022

Take this opportunity to book a free hybrid speed consulting session with Pharmetheus’ consultants in connection to WCoP 2022! Sign up here Pharmetheus is looking forward to World Conference on Pharmacometrics in Cape Town! 

Read More »

Support for Astegolimab dose rationale

A recent publication describes a model-based population PK and exposure-response analysis for Astegolimab in Patients with severe asthma. This analysis supports the rationale for  Astegolimab dosing as the highest dose tested in

Read More »

FDA Population Pharmacokinetics guidance

The Pharmetheus team just completed its review and training on the final FDA Population Pharmacokinetics guidance, confirming that our approaches and reports are fully compliant.  If you haven’t done so already, check

Read More »

Support to software solutions

Pharmetheus takes an active interest in several initiatives aiming to develop software solutions to support the MIDD applications of tomorrow. Our support for Pumas AI represents one of these initiatives: Pumas-AI, Inc.

Read More »

Open-source PBPK model update for new DDIs

Check out this new release of the OSP CYP3A4-DDI qualification report, where Pharmetheus in partnership with Boehringer Ingelheim contributed by adding a perpetrator contributed by adding a perpetrator (fluconazole) with 3 victims

Read More »